OakChart

Madrigal Pharmaceuticals Inc

MDGLHealthcare·Biotechnology·USA·Large·NASD·Nov 10 • 3:59 PM ET

432.600.00 (0.00%)
2026-11-11 14:42 CET
Market cap
10,049.12 USD m
Revenue, TTM
1,427.94 USD m
Net income, TTM
-155.46 USD m
Free cash flow, TTM
-168.65 USD m
EPS diluted, TTM
-5.98
P/E
-
Compare

Price

MDGL against its 20, 50 and 200-day averages
2050200beat
350.00400.00450.00500.00550.001.2M2.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MDGLclose 432.6020-day 434.6950-day 482.58200-day 497.03432.60

29.7% under 615.00 on 24 Dec 2025. Last 15 sessions, 36.5% high to low

Profile

MDGL
52-week range, 30% of the way up
353.54615

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

IndexRUI
Employees915
IPOFeb 06, 2007
Beta-0.99
ATR, 14d24.25
Rel volume0.00
Short float9.86%
Insider own6.77%
Inst own103.94%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap10.05B
Enterprise Value9.44B
Income-155.46M
Sales1.43B
Book/sh27.00
Cash/sh41.40
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees915
IPOFeb 06, 2007

Ratios

P/E-
Forward P/E61.83
PEG-
P/S7.04
P/B16.02
P/C10.45
P/FCF-
EV/EBITDA-
EV/Sales6.61
Quick Ratio2.78
Current Ratio3.05
Debt/Eq0.56
LT Debt/Eq0.56
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.98
EPS next Y7.00
EPS next Q1.43
EPS this Y84.30%
EPS next Y446.67%
EPS next 5Y-
EPS past 3/5Y9.32% 0.37%
Sales past 3/5Y- -
EPS Y/Y TTM54.57%
Sales Y/Y TTM92.80%
EPS Q/Q136.01%
Sales Q/Q50.13%
EarningsNov 03 BMO
EPS/Sales Surpr.312.00% 6.71%

Ownership

Insider Own6.77%
Insider Trans4.55%
Inst Own103.94%
Inst Trans-2.62%
ROA-11.12%
ROE-24.82%
ROIC-15.86%
Gross Margin90.85%
Oper. Margin-10.69%
Profit Margin-10.89%
SMA20-0.48%
SMA50-10.36%
SMA200-12.96%
Trades-

Technical

Shs Outstand23.22M
Shs Float21.66M
Short Float9.86%
Short Ratio6.08
Short Interest2.14M
52W High615.00 -29.66%
52W Low353.54 22.36%
Volatility7.90% 5.57%
ATR (14)24.25
RSI (14)44.21
Beta-0.99
Rel Volume0.00
Avg Volume351.65K
Volume0

Performance

Perf Week9.15%
Perf Month-7.40%
Perf Quarter-19.32%
Perf Half Y-15.22%
Perf YTD-25.71%
Perf Year-12.76%
Perf 3Y211.58%
Perf 5Y379.28%
Perf 10Y2639.71%
Recom1.18
Target Price688.32
Prev Close432.60
Price432.60
Change %0.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 24, 2026ResumedGGoldmanBuy$704+62.7%
Sep 23, 2026InitiatedCCitigroupBuy$725+67.6%
Aug 04, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$605+39.9%
Jul 27, 2026InitiatedWWells FargoOverweight$685+58.3%
Jan 28, 2026InitiatedBBarclaysOverweight$964+122.8%
Jan 06, 2026DowngradeWWolfe ResearchOutperform → Peer Perform
Nov 05, 2025UpgradeCCantor FitzgeraldNeutral → Overweight
Nov 03, 2025UpgradeBBofA SecuritiesUnderperform → Neutral$445+2.9%
Oct 15, 2025InitiatedTTruistBuy$580+34.1%
Sep 04, 2025ResumedHH.C. WainwrightBuy$500+15.6%

Peers

Mkt cap
TickerCompanyMkt cap
VKTXViking Therapeutics Inc3.74B
IVAInventiva ADR915.75M
ALTAltimmune Inc394.87M
NVONovo Nordisk ADR135.84B
SGMTSagimet Biosciences Inc794.16M
RYTMRhythm Pharmaceuticals Inc7.89B
ARWRArrowhead Pharmaceuticals Inc6.99B
LLYLilly(Eli) & Co1330.21B
GSKGSK Plc ADR100.93B
NAMSNewAmsterdam Pharma Company NV2.33B

Insider trading

latest 14 of 71
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BAKER BROS. ADVISORS LPDirectorNov 06 '26Buy384.3276,14029,262,4312,040,682Nov 06 05:30 PM
BAKER BROS. ADVISORS LPDirectorNov 04 '26Buy367.7115,6665,760,6021,964,542Nov 06 05:30 PM
Kelley Shannon TGeneral CounselNov 06 '26Sale400.001,077430,80010,397Nov 06 04:36 PM
SHANNON KELLEYOfficerNov 06 '26Proposed Sale400.101,077430,908Nov 06 04:27 PM
PAUL FRIEDMANDirectorSep 28 '26Proposed Sale516.5650,00025,828,000Sep 28 04:19 PM
Sibold William JohnPresident and CEOSep 09 '26Sale535.596,3623,407,397202,967Sep 11 04:57 PM
Sibold William JohnPresident and CEOSep 11 '26Sale542.395,2212,831,801197,746Sep 11 04:57 PM
WILLIAM SIBOLDDirectorSep 11 '26Proposed Sale533.125,2212,783,420Sep 11 04:33 PM
William John SiboldOfficer and DirectorSep 09 '26Proposed Sale534.166,3623,398,326Sep 09 06:05 PM
Kelley Shannon TGeneral CounselAug 17 '26Sale514.97664341,94011,474Aug 20 04:20 PM
Shannon KelleyOfficerAug 17 '26Proposed Sale507.56664337,020Aug 20 04:18 PM
Sibold William JohnPresident and CEOJul 20 '26Sale547.302,5001,368,253209,329Jul 20 09:16 PM
William SiboldOfficer and DirectorJul 20 '26Proposed Sale553.482,5001,383,700Jul 20 09:11 PM
Soergel DavidChief Medical OfficerJun 01 '26Sale495.741,042516,56110,033Jun 01 07:49 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
VBVanguard Morningstar Small-Cap ETFAUM: 79.96B
XBIState Street SPDR S&P Biotech ETFAUM: 10.53B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.56B
VXFVanguard Extended Market Index ETFAUM: 30.61B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.05B
IBBiShares Biotechnology ETFAUM: 11.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.32B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.16B
IWRiShares Russell Mid-Cap ETFAUM: 58.75B

News

latest 14 of 206
  • Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations (Newsfile)
  • Madrigals MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales (Stocktwits)
  • Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra (GlobeNewswire)
  • Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations (Newsfile)
  • MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside (Stocktwits) -8.08%
  • Loading…
  • How Did Madrigal Pharmaceuticals Turn a $114 Million Loss Into a Q3 Profit as Rezdiffra Sales Surpassed $1 Billion? (InvestorsHub)
  • Madrigal Turns Its First Profit On Rezdiffra Strength, But Slowing Growth Rates And 2027 Pricing Pressure Keep The Debate Alive (Earnings Whispers)
  • MediWound's EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus (Nasdaq: MDWD) (FinanceWire)
  • Madrigal: Q3 Earnings Snapshot (Associated Press)
  • Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH (GlobeNewswire)
  • Madrigal Needs ResDifera Volume To Outrun Pricing And Cost Pressure As Shares Hit Lows (Earnings Whispers)
  • Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-031.830-0.8631.830431.3404.1719
2026Q22026-07-30-1.990-2.677-1.988364.3352.1317
2026Q12026-05-06-3.250-4.230-3.251311.34301.0517
2025Q42026-02-19-2.570-0.895-2.566321.1312.5117
2025Q32025-11-04-5.080-2.285-5.079287.27247.3416
2025Q22025-08-05-1.900-3.554-1.904212.8162.0316
2025Q12025-05-01-3.320-3.749-3.315137.25114.6616
2024Q42025-02-26-2.710-3.920-2.709103.3299.0917
2024Q32024-10-31-4.920-6.748-4.91962.2034.6017
2024Q22024-08-07-7.100-7.537-7.10114.644.2517
2024Q12024-05-07-7.380-6.285-7.3770.000.0013
2023Q42024-02-28-5.680-5.239-5.6780.000.0013
2023Q32023-11-06-5.340-4.896-5.3440.000.0012
2023Q22023-08-08-4.690-4.592-4.6860.000.0011
2023Q12023-05-09-4.230-4.957-4.2280.000.0011
2022Q42023-02-23-4.980-4.626-4.9840.000.0013

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5.450-5.509-5.4530.000.00
2020FY-13.090-12.925-13.0930.000.00
2021FY-14.630-14.672-14.6260.000.00
2022FY-17.230-16.824-17.2340.000.00
2023FY-19.990-19.443-19.9930.000.00
2024FY-21.900-23.404-21.901180.13174.64
2025FY-12.850-11.038-12.850958.4949.55
2026FY--2.018--1,584
2027FY-6.996--2,181
2028FY-20.816--2,888
2029FY-36.038--3,800
2030FY-50.935--4,727

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0918180477.02462.11503
2026Q4S2026-11-0717170476.96462.11503
2026Q4S2026-11-0518170475.3447503
2026Q4S2026-11-0418170475.3447503
2026Q4S2026-11-0318170475.3447503
2026Q4S2026-10-191822444.51418.51465.8
2026Q4S2026-10-131821444.78418.51465.8
2026Q4S2026-10-101863444.44418.51465.8
2026Q4S2026-10-091873444.44418.51465.8
2026Q4S2026-10-051865444.71418.51478.32
2026Q4S2026-09-291865444.69418.51478.32
2026Q4S2026-09-261865444.68418.51478.32
2026Q4S2026-09-231866444.68418.51478.32
2026Q4S2026-08-241666443.78418.51478.32

Estimate history

EPS, annual-2.54-2.217-5.453-13.093-14.626-17.234-19.993-21.901-12.85-5.976
Period201720182019202020212022202320242025TTM
EPS, quarterly-4.919-2.709-3.315-1.904-5.079-2.566-3.251-1.9881.829
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000180.133958.4031427.94
Period201720182019202020212022202320242025TTM
Sales, quarterly62.175103.32137.25212.802287.268321.083311.337364.252431.268
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual14.22815.40915.42915.50817.10318.10319.87522.00522.84223.222
Period201720182019202020212022202320242025MRQ
Shares, quarterly21.80622.00522.18822.22122.70422.84223.04223.09423.222
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,427.94958.40180.130.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A130.6757.657.330.530.470.410.470.110.10
Gross Profit1,297.27900.75172.80-0.53-0.47-0.41-0.47-0.11-0.10
Selling, General and Administrative Excl. Other1,449.921,200.85670.68379.97293.10241.58205.8594.8640.36
Research and Development386.34387.02235.62271.82244.97205.16184.8172.3225.39
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-152.65-300.10-497.88-380.50-293.57-241.98-206.32-94.97-40.46
Interest Expense32.1222.3114.6712.713.960.000.000.000.00
Unusual Expense0.002.780.000.000.000.500.35-0.23
Net Income Before Taxes-155.46-288.28-465.89-373.63-295.35-241.85-202.24-83.95-32.81
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-155.46-288.28-465.89-373.63-295.35-241.85-202.24-83.95-32.81
Net Income From Continuing Operations-155.46-288.28-465.89-373.63-295.35-241.85-202.24-83.95-32.81
Net Income-155.46-288.28-465.89-373.63-295.35-241.85-202.24-83.95-32.81
EPS (Recurring)-5.13-12.76-21.90-19.99-17.23-14.60-13.08-5.45-2.21
EPS (Basic, Before Extraordinaries)-5.91-12.85-21.90-19.99-17.23-14.63-13.09-5.45-2.22
EPS (Diluted)-5.98-12.85-21.90-19.99-17.23-14.63-13.09-5.45-2.22
EBITDA-150.24-298.59-496.78-379.97-293.10-241.58-205.85-94.86-40.36
Non-Operating Income (Expense)29.3136.9046.6519.582.190.644.4311.027.87
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense134.1298.1379.8849.7331.6226.8720.7322.7613.49
Price To Sales Ratio10.7013.6336.44------
Gross Margin90.8593.9895.93------
Operating Margin-10.69-31.31-276.39------
Net Margin-10.89-30.08-258.64------
Shares Outstanding23.2222.8422.0019.8818.1017.1015.5115.4315.41
Market Capitalization10,049.1210,049.126,730.044,568.044,964.261,448.811,719.411,405.741,735.10

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue431.27364.25311.34321.08287.27212.80137.25103.32
Cost of Goods Sold Incl. D&A38.2140.3927.2324.8418.489.444.893.81
Gross Profit393.06323.86284.10296.24268.79203.36132.3699.51
Selling, General and Administrative Excl. Other337.07380.17376.83355.85382.76250.56211.67166.51
Research and Development71.3690.80108.31115.88173.6553.7043.7925.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income55.99-56.31-92.72-59.61-113.97-47.20-79.31-67.00
Interest Expense8.077.947.828.307.453.263.303.50
Unusual Expense0.000.000.000.002.780.000.000.00
Net Income Before Taxes55.44-57.94-94.39-58.58-114.19-42.28-73.24-59.42
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income55.44-57.94-94.39-58.58-114.19-42.28-73.24-59.42
Net Income From Continuing Operations55.44-57.94-94.39-58.58-114.19-42.28-73.24-59.42
Net Income55.44-57.94-94.39-58.58-114.19-42.28-73.24-59.42
EPS (Recurring)1.83-1.99-3.25-2.57-4.99-1.90-3.32-2.71
EPS (Basic, Before Extraordinaries)1.90-1.99-3.25-2.57-5.08-1.90-3.32-2.71
EPS (Diluted)1.83-1.99-3.25-2.57-5.08-1.90-3.32-2.71
EBITDA57.24-55.93-92.34-59.22-113.62-46.83-78.93-66.63
Non-Operating Income (Expense)7.526.316.159.3310.028.199.3711.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense38.9535.3734.0225.7926.2525.1620.9317.68
Price To Sales Ratio10.7012.1913.4213.8713.9213.0423.0637.57
Gross Margin91.1488.9191.2592.2693.5795.5696.4496.31
Operating Margin12.98-15.46-29.78-18.56-39.68-22.18-57.79-64.84
Net Margin12.86-15.91-30.32-18.24-39.75-19.87-53.36-57.51
Shares Outstanding23.2223.0923.0422.8422.7022.2222.1922.00
Market Capitalization10,049.1212,379.7612,008.4013,225.7610,223.076,719.617,313.626,730.04

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments988.65931.25634.13358.77270.35284.15439.05483.72191.53
Short Term Receivables134.4853.820.000.000.000.000.000.000.00
Inventories74.8434.070.000.000.000.000.000.000.00
Other Current Assets47.8013.793.152.601.341.011.151.480.48
Total Current Assets1,245.771,032.93637.28361.37271.68285.16440.20485.20192.01
Net Property, Plant & Equipment6.444.593.271.201.651.831.860.230.30
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets7.384.730.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets1,259.591,042.25640.55362.57273.33287.00442.06485.43192.31
Short Term Debt Incl. Current Port. of LT Debt1.020.980.530.600.410.320.320.000.00
Accounts Payable48.8843.6028.0423.8321.381.021.182.491.93
Other Current Liabilities260.39124.6989.9891.4655.0545.2223.645.968.12
Total Current Liabilities310.29169.28118.55115.8976.8446.5625.138.4410.05
Long Term Debt346.61118.59116.6749.290.390.470.360.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities656.90287.86235.21165.1877.2247.0225.498.4410.05
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity602.69754.38405.33197.39196.11239.97416.56476.98182.26
Total Shareholders Equity602.69754.38405.33197.39196.11239.97416.56476.98182.26
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity602.69754.38405.33197.39196.11239.97416.56476.98182.26
Total Liabilities & Stockholders Equity1,259.591,042.25640.55362.57273.33287.00442.06485.43192.31
Book Value Per Share26.3934.2820.3910.9011.4715.4727.0030.9512.81
Tangible Book Value Per Share26.0634.0720.3910.9011.4715.4727.0030.9512.81
Full-Time Employees91552837692714229178
Price to Book Ratio16.028.66192.33465.267.397.183.373.6421.12
Return on Assets-25.05-55.37-74.49-92.89-86.32-55.48-18.10-9.68-26.68
Return on Equity-42.49-80.35-123.98-150.12-110.92-61.61-18.79-9.95-28.49
Return on Invested Capital-30.37-53.37-71.58-119.73-123.08-84.11-20.13-6.88-17.09
Quick Ratio3.775.905.383.123.546.1317.5257.4619.10
Current Ratio4.016.105.383.123.546.1317.5257.4619.10

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-155.46-288.28-465.89-373.63-295.35-241.85-202.24-83.95-32.81
Depreciation3.461.511.100.530.470.410.470.110.10
Other Funds (Non Cash)143.47105.7281.5752.1532.4226.8720.7322.7613.49
Funds from Operations-8.53-181.06-383.23-320.95-262.46-214.57-181.04-61.08-19.23
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-148.48-8.50-72.34-3.2837.6030.6523.4819.45-6.28
Cash from Operating Activities-157.01-189.55-455.57-324.23-224.86-183.92-157.56-41.62-25.51
Capital Expenditures-11.64-3.47-6.46-1.48-0.22-0.21-0.33-0.17-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments359.4035.79-267.92-501.04206.90-4.85160.1130.88-380.05
Purchase of Investments-654.53-1,047.51-1,131.21-834.44-143.48-394.12-329.34-619.30-614.36
Sale Or Maturity of Investments1,013.931,083.30863.28333.40350.38389.27489.46650.18234.30
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities347.7632.32-274.39-502.52206.69-5.05159.7830.71-380.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock25.3438.05735.06530.48264.34171.245.090.23314.33
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock25.3438.05735.06530.48264.34171.245.090.23314.33
Proceedsfrom Stock Options0.000.00397.49260.19255.38170.214.420.00311.82
Issuance or Reduction of Debt, Net-0.98217.930.0064.6449.110.000.000.000.00
Change in Long Term Debt-0.98217.930.0064.6449.110.000.000.000.00
Issuance of Long Term Debt-0.98339.590.0064.6449.110.000.000.000.00
Reduction of Long Term Debt0.00-121.660.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities24.36255.98735.06595.12313.45171.245.090.23314.33
Exchange Rate Effect-0.01-------
Net Change in Cash214.7598.765.10-231.63295.28-17.737.31-10.68-91.25
Free Cash Flow-168.65-190.02-457.03-325.71-225.07-184.13-157.90-41.80-25.53
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments961.77838.91817.93988.651,114.75802.02
Short Term Receivables227.38192.31187.36134.48113.2879.23
Inventories122.5999.39112.0774.8469.3263.50
Other Current Assets75.3768.5764.9547.8049.3358.60
Total Current Assets1,387.111,199.181,182.311,245.771,346.681,003.36
Net Property, Plant & Equipment26.8117.1714.246.448.307.48
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets7.097.197.287.387.484.55
Other Assets13.3821.1123.500.000.000.00
Total Assets1,434.391,244.641,227.331,259.591,362.461,015.38
Short Term Debt Incl. Current Port. of LT Debt1.011.031.701.021.081.05
Accounts Payable61.3734.5160.8048.8844.9437.98
Other Current Liabilities391.86338.66275.76260.39345.38157.48
Total Current Liabilities454.24374.20338.26310.29391.41196.50
Long Term Debt353.20346.72345.61346.61345.32122.90
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities807.45720.92683.87656.90736.73319.40
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity626.94523.72543.45602.69625.73695.98
Total Shareholders Equity626.94523.72543.45602.69625.73695.98
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity626.94523.72543.45602.69625.73695.98
Total Liabilities & Stockholders Equity1,434.391,244.641,227.331,259.591,362.461,015.38
Book Value Per Share27.0022.6823.5926.3927.5631.32
Tangible Book Value Per Share26.6922.3723.2726.0627.2331.12
Full-Time Employees---915--
Price to Book Ratio16.0222.7719.8421.1314.649.45
Return on Assets-11.12-28.77-27.83-25.05-23.74-26.65
Return on Equity-24.82-53.31-49.35-42.49-41.22-36.30
Return on Invested Capital5.66-6.66-10.62-6.17-11.76-5.16
Quick Ratio2.782.943.163.773.264.78
Current Ratio3.053.203.504.013.445.11

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income55.44-57.94-94.39-58.58-114.19-42.28
Depreciation1.251.430.390.390.360.38
Other Funds (Non Cash)37.4346.4132.4427.1930.5826.53
Funds from Operations94.12-10.09-61.57-30.99-83.25-15.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital26.4333.42-105.86-102.47163.10-31.68
Cash from Operating Activities120.5623.33-167.44-133.4679.85-47.05
Capital Expenditures-3.93-4.25-3.850.39-3.860.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments97.7238.45196.0427.19-203.1447.86
Purchase of Investments-134.90-148.85-157.83-212.96-478.21-225.53
Sale Or Maturity of Investments232.62187.30353.87240.15275.07273.39
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities93.7934.20192.1927.58-207.0047.86
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock9.963.112.339.9417.731.74
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock9.963.112.339.9417.731.74
Proceedsfrom Stock Options0.000.000.000.000.00-8.64
Issuance or Reduction of Debt, Net0.000.000.00-0.98218.910.00
Change in Long Term Debt0.000.000.00-0.98218.910.00
Issuance of Long Term Debt0.000.000.00-0.98340.580.00
Reduction of Long Term Debt0.000.000.000.00-121.660.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities9.963.112.338.96236.651.74
Exchange Rate Effect-1.75-----
Net Change in Cash222.5760.6928.41-96.91109.502.55
Free Cash Flow116.6319.08-171.28-133.0778.99-47.05

Revenue breakdown

Pharmaceutical Preparations2024: 180.13M 2025: 958.40M
United States2024: 180.13M 2025: 958.40M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.86%2.1M21.7M278.02K
2026-10-1510.19%2.2M21.5M293.99K
2026-09-3011.13%2.4M21.5M292.59K
2026-09-1510.47%2.3M21.5M344.75K
2026-08-3110.41%2.2M21.5M354.05K
2026-08-149.41%2.0M21.5M360.53K
2026-07-319.13%2.0M21.5M359.09K
2026-07-159.60%2.1M21.5M326.87K
2026-06-3016.27%3.5M21.7M332.94K
2026-06-1517.44%3.8M21.7M312.01K
2026-05-2917.63%3.8M21.7M315.65K
2026-05-1518.51%3.9M21.1M347.78K
2026-04-3018.40%3.9M21.0M349.69K
2026-04-1519.26%4.0M20.8M364.81K
2026-03-3118.75%3.9M20.9M378.02K
2026-03-1318.85%3.9M20.9M348.20K
2026-02-2717.95%3.7M20.9M341.97K
2026-02-1317.36%3.6M20.9M326.66K
2026-01-3019.35%4.0M20.6M359.10K
2026-01-1518.74%3.9M20.6M353.58K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call300128.51370.001.6675.000.000.942-0.6750.082
call310119.8127.10.001.5573.000.000.938-0.6630.087
call320109.3117.288.001.44918.000.000.933-0.6500.092
call330101.6107.479.901.3525.000.000.921-0.7050.105
call34091.6097.6069.601.2548.000.000.914-0.6870.111
call35081.9087.9055.001.1635.000.000.901-0.7170.124
call36072.3078.3029.901.0777.000.000.851-1.0370.165
call37060.7068.9039.661.00043.000.000.836-0.9920.175
call38052.3059.7035.100.9569.000.000.819-0.9420.187
call39044.1050.8039.000.89331.000.000.786-0.9610.207
call40035.0042.5036.700.82850.000.000.746-0.9730.228
call41027.0034.8030.000.77893.000.000.699-0.9360.247
call42022.0027.6020.360.74322.002.000.624-1.0310.270
call43015.6022.5018.240.74212618.000.547-1.0460.281
call44010.0017.7013.500.73530.000.000.469-1.0440.282
call4506.9013.608.000.7271010.000.392-0.9960.273
call4603.007.607.550.61415.002.000.297-0.7970.246
call4702.405.604.050.59817634.000.218-0.6490.209
call4800.158.202.800.6852420.000.195-0.6910.196
call4900.107.702.300.76714.000.000.179-0.7330.186
call5000.201.751.060.62663.0019.000.089-0.3670.114
call5100.057.301.000.6887.000.000.082-0.3810.108
call5200.057.201.190.74910.000.000.077-0.3930.102
call5300.057.101.200.80757.000.000.072-0.4040.098
call5400.004.903.800.8632.000.000.068-0.4140.094
call5500.003.600.250.91720.001.000.065-0.4230.090
call5600.004.900.350.96915.000.000.062-0.4320.087
call5700.004.903.621.02013.000.000.060-0.4400.084
call5800.004.900.351.0709.000.000.058-0.4470.082
call5900.004.900.301.11820.000.000.056-0.4550.080
call6000.004.900.251.16548.000.000.054-0.4610.078
call6100.004.900.001.2100.000.000.052-0.4680.076
call6200.004.902.251.2555.000.000.051-0.4740.074
call6300.003.500.251.2988.000.000.049-0.4790.072
call6400.054.901.001.3411.000.000.048-0.4850.071
call6500.004.900.001.3820.000.000.047-0.4900.069
call6600.004.900.001.4220.000.000.046-0.4950.068
call6700.004.900.001.4620.000.000.045-0.5000.067
call6800.004.905.101.5013.000.000.044-0.5040.066
call6900.004.900.001.5390.000.000.043-0.5090.065
call7000.004.900.001.5760.000.000.042-0.5130.064
call7100.000.250.251.58827.000.000.041-0.5090.064
call7200.004.900.001.2530.000.000.009-0.1100.017
put3000.004.900.001.5460.000.00-0.058-0.6420.082
put3100.004.900.001.4330.000.00-0.062-0.6290.087
put3200.003.000.501.32335.000.00-0.067-0.6140.092
put3300.003.608.001.26618.000.00-0.079-0.6690.105
put3400.003.501.771.15834.004.00-0.086-0.6490.111
put3500.003.901.991.08466.004.00-0.099-0.6780.124
put3600.057.4016.751.19731.000.00-0.149-0.9970.165
put3700.057.708.901.0771010.00-0.164-0.9520.175
put3800.257.203.320.95665.000.00-0.181-0.9000.187
put3900.558.206.000.88510.000.00-0.214-0.9190.207
put4001.009.405.800.8121910.00-0.254-0.9290.228
put4103.0010.008.900.70320.000.00-0.301-0.8910.247
put4206.0014.4010.550.72725.003.00-0.376-0.9850.270
put43011.0018.0034.600.6911730.00-0.453-0.9990.281
put44016.0023.1019.530.68124.002.00-0.531-0.9950.282
put45022.0028.6056.430.65716.000.00-0.608-0.9470.273
put46029.0036.2025.550.6839.000.00-0.703-0.7460.246
put47037.0043.001090.6501670.00-0.782-0.5980.209
put48045.5052.8086.400.7311550.00-0.805-0.6390.196
put49054.8061.8094.980.76311.000.00-0.821-0.6790.186
put50064.4070.3093.670.7517.000.00-0.911-0.3120.114
put51074.2080.40120.520.8285.000.00-0.918-0.3250.108
put52084.0092.1065.901.0059.000.00-0.923-0.3360.102
put53093.90102134.931.0628.000.00-0.928-0.3460.098
put540103.8111.1147.21.0745.000.00-0.932-0.3550.094
put550113.7121.1144.51.1362.000.00-0.935-0.3630.090
put560123.7131160.41.1890.000.00-0.938-0.3710.087
put570133.7141.3170.51.2700.000.00-0.940-0.3780.084
put580143.6151.4174.21.3350.000.00-0.942-0.3840.082
put590153.6160.9184.11.3510.000.00-0.944-0.3900.080
put600163.6171.4177.11.4440.000.00-0.946-0.3960.078
put610173.6181.2210.21.4810.000.00-0.948-0.4010.076
put620183.6191.9197.11.5882.000.00-0.949-0.4060.074
put630193.6201.7207.11.6230.000.00-0.951-0.4100.072
put640203.6211.22171.6300.000.00-0.952-0.4150.071
put650213.6220.92271.6520.000.00-0.953-0.4190.069
put660223.6231.20.001.7240.000.00-0.954-0.4230.068
put670233.6241.70.001.7430.000.00-0.955-0.4260.067
put680243.6251.3230.21.8230.000.00-0.956-0.4300.066
put690253.6260.9253.11.8300.000.00-0.957-0.4330.065
put700263.6271.2245.41.9010.000.00-0.958-0.4360.064
put710273.6280.92581.9140.000.00-0.991-0.0310.017
put720283.6290.92681.9550.000.00-0.991-0.0310.017

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-06SCHEDULE 13D/ASEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-183Initial statement of beneficial ownership of securities2026-08-11SEC
2026-08-128-KCurrent report2026-08-11SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-20144Filing for proposed sale of securities under Rule 144.SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-17S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-178-KCurrent report2026-06-16SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1135.02M2430.80K1
2026-100000
2026-09006.24M2
2026-0800341.94K1
2026-07001.37M1
2026-0600516.56K1
2026-05003.36M2
2026-040000
2026-03002.63M6
2026-020000
2026-010025.70M9
2025-120027.79M4
2025-110013.54M3

Institutional holders

Manager% owned
BAKER BROS. ADVISORS LP9.30%
RTW INVESTMENTS, LP8.65%
Jupiter Topco LLC8.40%
Avoro Capital Advisors LLC7.95%
PAULSON & CO. INC.5.81%
BlackRock, Inc.5.21%
VANGUARD CAPITAL MANAGEMENT LLC3.62%
WELLINGTON MANAGEMENT GROUP LLP3.58%
VANGUARD PORTFOLIO MANAGEMENT LLC3.39%
STATE STREET CORP2.29%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.54%
VANGUARD HEALTH CARE FUND2.44%
VANGUARD SMALL-CAP INDEX FUND1.84%
Janus Henderson Forty Fund1.47%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.06%
Janus Henderson Enterprise Fund1.01%
VANGUARD EXTENDED MARKET INDEX FUND0.94%
State Street(R) SPDR(R) S&P(R) Biotech ETF0.92%
VANGUARD EXPLORER FUND0.82%
Fidelity Small Cap Index Fund0.74%

OakChart. MDGL. Cached 15 minutes.